false
0000882291
0000882291
2025-08-21
2025-08-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 21, 2025
Aethlon
Medical, Inc.
(Exact name of registrant as specified in its
charter)
Nevada |
001-37487 |
13-3632859 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (619) 941-0360
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
|
AEMD |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosures.
On August 20, 2025, Aethlon
Medical, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that may be
used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the
Company’s website, www.aethlonmedical.com. The Presentation is furnished as Exhibit 99.1 hereto.
The information in the
Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in
such a filing. The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not
intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form
8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment
decision with respect to any security of the Company.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Description |
99.1 |
|
Presentation Materials |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL Document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 21, 2025 |
Aethlon Medical, Inc. |
|
|
|
|
By: |
/s/ James B. Frakes |
|
Name:
Title: |
James B. Frakes
Chief Executive Officer and Chief Financial Officer |